Annexon, Inc.
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
ANNX | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 1400 SIERRA POINT PARKWAY, 94005 BRISBANE
- Website:
- https://annexonbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Annexon, Inc. is a clinical-stage biopharmaceutical company developing a new class of medicines for patients with classical complement-mediated diseases. The company's scientific approach is focused on stopping C1q, the initiating molecule of the classical complement pathway, to treat a range of devastating autoimmune, neurodegenerative, and ophthalmic diseases. Its pipeline of complement inhibitors targets disorders of the body, brain, and eye. Annexon aims to deliver transformative therapies by precisely blocking the start of the complement cascade to prevent inflammation and tissue damage.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Annexon, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Annexon, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Annexon, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
